Europe Cervical Cancer Screening Market Forecast Report by Europe Cervical Cancer Test (Screening) Market (Pap Smear Test Market, HPV DNA Test Market) Countries and Company Analysis, 2024-2032
Buy NowEurope Cervical Cancer Screening Market Analysis
Europe Cervical Cancer Screening Market was US$ 9.42 Billion in 2023 and will grow US$ 14.63 Billion by 2032, with a CAGR of 5.01 % from 2024 to 2032. The rise in female elderly population, rising cervical cancer prevalence, and improvements in cervical cancer screening are driving growth in the cervical cancer screening market. In addition, advantageous health reimbursement, proactive government assistance, and growing awareness of women's health are a few of the key elements anticipated to boost the cervical cancer screening market in Europe.
Europe Cervical Cancer Screening Market Overview
One type of cancer brought on by unchecked cell proliferation is cervical cancer. A cervix infection with the human papillomavirus (HPV) is linked to an increased risk of cervical cancer. Cervical cancer is the second greatest cause of cancer-related mortality for women between the ages of 15 and 44 in Europe and the ninth most common type of cancer that affects women overall. In the nations that make up the European Union, cervical cancer affects over 100,000 women annually. This disease is a key measure of how well healthcare systems handle cancer. The effectiveness of treatment and early identification both affect the survival rates for cervical cancer. Fortunately, if precancerous cells are found and treated before they spread, cervical cancer can be generally avoided. Since more than 90% of cases of cervical cancer are caused by the human papillomavirus (HPV), vaccination against the main HPV types linked to the disease is essential to lowering its incidence.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 9.42 Billion |
|
Market Forecast in 2032 |
US$ 14.63 Billion |
|
Market Growth Rate (2024-2032) |
5.01% |
Growth Factors in the Cervical Cancer Screening Industry
Technological Developments
As screening technologies continue to progress, the market for cervical cancer screening is expected to rise significantly. Advances like HPV DNA testing, automated screening devices, and liquid-based cytology improve the precision, efficacy, and accessibility of cervical cancer screening initiatives. The incidence and fatality rates of cervical cancer are decreased by the early diagnosis of precancerous lesions and HPV infections made possible by these technical developments. In order to enhance screening procedures and broaden the scope of screening, manufacturers consistently allocate resources to research and development. This helps to propel the market forward and empower women's health.
Artificial Intelligence (AI) and Digital Health Solutions Integration
Cervical cancer screening procedures are revolutionized by the integration of artificial intelligence (AI) and digital health technologies, which present chances to enhance patient care, accuracy, and efficiency. Artificial intelligence (AI) systems examine cervical pictures, Pap smear results, and HPV test data to help medical professionals interpret screening results, minimize diagnostic errors, and improve patient management techniques. Digital health platforms improve the accessibility and continuity of care for women in underserved or distant locations by facilitating centralized data administration, telemedicine consultations, and remote screening. In addition to facilitating the delivery of tailored and precision medicine techniques in cervical cancer screening and management, the adoption of AI and digital health solutions promotes market growth.
Germany Cervical Cancer Screening Market Overview:
Within the healthcare sector, Germany's cervical cancer screening market is a sizable and expanding business. Germany's strong healthcare system, which prioritizes early identification and preventive care, is the market's main driver. Regular screening programs, backed by insurance coverage and public health campaigns, are widely implemented. These programs include Pap smears and HPV (human papillomavirus) testing.
Germany's market benefits from state-of-the-art facilities for healthcare and modern technology. Molecular diagnostics and liquid-based cytology are two examples of screening technology innovations that are improving detection rates and accuracy. Moreover, rising screening rates are a result of growing knowledge about cervical cancer and the efficacy of vaccinations.
The market is growing because of government regulations and recommendations, such as the inclusion of HPV vaccination in national immunization regimens. The need for more accurate and effective screening techniques is also being driven by the nation's emphasis on early intervention and individualized medicine.
Effective management and prevention of cervical cancer are ensured by robust public health initiatives, cutting-edge technology, and a supportive policy environment, which collectively define Germany's cervical cancer screening industry.
Europe Cervical Cancer Screening Market Company Overview
Some of the industry leaders seen in the Europe Cervical Cancer Screening Market Includes Abbott laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, Cardinal Health.
Europe Cervical Cancer Screening Market News
In June 2022, an official "human papillomavirus (HPV) self-sampling solution" launch has been announced in the regions accepting the CE mark by the international healthcare corporation based in Switzerland, F. Hoffmann-La Roche Ltd. The primary use of this test kit is for HPV screening, which identifies women who may be at risk of cervical cancer.
In March 2021, GynTect is an advanced cervical cancer test. Oncgnostics GmbH, a leading producer of cancer-related in-vitro diagnostic tests, and EUROIMMUN, a well-known supplier of immunodiagnostic laboratory solutions, announced a strategic partnership to commercialize this test. Under the terms of the partnership, EUROIMMUN would sell GynTect throughout Europe, notably in Turkey, Italy, Portugal, and Poland.
Europe Cervical Cancer Test (Screening) – Market breakup in 2 viewpoints:
- Pap Smear Test Market
- HPV DNA Test Market
Counties - covered in 2 Viewpoints:
- Pap Smear Market
- HPV DNA Market
- United Kingdom
- France
- Germany
- Italy
- Spain
- Sweden
- Switzerland
- Norway
- Netherlands
All the Key players have been covered from 4 Viewpoints:
- Overviews
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis:
- Abbott laboratories
- Hologic Corporation
- Becton
- Siemens AG
- Roche Diagnostics
- Quest Diagnostics
- Cardinal Health
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered |
Test Population, Market, and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Key Questions Answered in This Report:
- How big is the Europe Cervical Cancer Screening industry?
- What is the Europe Cervical Cancer Screening industry growth rate?
- Who are the key players in Europe Cervical Cancer Screening industry?
- What are the factors driving the Europe Cervical Cancer Screening industry?
- Which Region held the largest market share in the Europe Cervical Cancer Screening industry?
- What segments are covered in the Europe Cervical Cancer Screening Market report?
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Cervical Cancer Screening Analysis
5.1 Europe Cervical Cancer Market
5.2 Europe Cervical Cancer Population
6. Europe Cervical Cancer Test (Screening) Analysis
6.1 Europe Cervical Cancer Test Population
6.1.1 Pap smear Test Population
6.1.2 HPV DNA Test Population
6.2 Europe Cervical Cancer Test (Screening) Market
6.2.1 Pap Smear Test Market
6.2.2 HPV DNA Test Market
7. By Countries - Europe Cervical Cancer Test Market & Population Share Analysis
7.1 Europe Cervical Cancer Test Population Share
7.1.1 Pap Smear Population
7.1.2 HPV DNA Population
7.2 Europe Cervical Cancer Market Share
7.2.1 Pap Smear Market
7.2.2 HPV DNA Market
8. United Kingdom – Cervical Cancer Test Analysis
8.1 Population – Cervical Cancer Test (Screening)
8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population
8.2 Market – Cervical Cancer Test (Screening)
8.2.1 Pap smear Test Market
8.2.2 HPV DNA Test Market
9. France – Cervical Cancer Test Analysis
9.1 Population – Cervical Cancer Test (Screening)
9.1.1 Pap smear Test Population
9.1.2 HPV DNA Test Population
9.2 Market – Cervical Cancer Test (Screening)
9.2.1 Pap Smear Test Market
9.2.2 HPV DNA Test Market
10. Germany – Cervical Cancer Test Analysis
10.1 Population – Cervical Cancer Test (Screening)
10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population
10.2 Market – Cervical Cancer Test (Screening)
10.2.1 Pap Smear Test Market
10.2.2 HPV DNA Test Market
11. Italy – Cervical Cancer Test Analysis
11.1 Population – Cervical Cancer Test (Screening)
11.1.1 Pap smear Test Population
11.1.2 HPV DNA Test Population
11.2 Market – Cervical Cancer Test (Screening)
11.2.1 Pap Smear Test Market
11.2.2 HPV DNA Test Market
12. Spain – Cervical Cancer Test Analysis
12.1 Population – Cervical Cancer Test (Screening)
12.1.1 Pap smear Test Population
12.1.2 HPV DNA Test Population
12.2 Market – Cervical Cancer Test (Screening)
12.2.1 Pap Smear Test Market
12.2.2 HPV DNA Test Market
13. Sweden – Cervical Cancer Test Analysis
13.1 Population – Cervical Cancer Test (Screening)
13.1.1 Pap smear Test Population
13.1.2 HPV DNA Test Population
13.2 Market – Cervical Cancer Test (Screening)
13.2.1 Pap Smear Test Market
13.2.2 HPV DNA Test Market
14. Switzerland – Cervical Cancer Test Analysis
14.1 Population – Cervical Cancer Test (Screening)
14.1.1 Pap smear Test Population
14.1.2 HPV DNA Test Population
14.2 Market – Cervical Cancer Test (Screening)
14.2.1 Pap Smear Test Market
14.2.2 HPV DNA Test Market
15. Norway – Cervical Cancer Test Analysis
15.1 Population – Cervical Cancer Test (Screening)
15.1.1 Pap smear Test Population
15.1.2 HPV DNA Test Population
15.2 Market – Cervical Cancer Test (Screening)
15.2.1 Pap Smear Test Market
15.2.2 HPV DNA Test Market
16. Netherlands – Cervical Cancer Test Analysis
16.1 Population – Cervical Cancer Test (Screening)
16.1.1 Pap smear Test Population
16.1.2 HPV DNA Test Population
16.2 Market – Cervical Cancer Test (Screening)
16.2.1 Pap Smear Test Market
16.2.2 HPV DNA Test Market
17. Porter’s Five Forces
17.1 Bargaining Power of Buyer
17.2 Bargaining Power of Supplier
17.3 Threat of New Entrants
17.4 Rivalry among Existing Competitors
17.5 Threat of Substitute Products
18. SWOT Analysis
18.1 Strengths
18.2 Weaknesses
18.3 Opportunities
18.4 Threats
19. Company Analysis
19.1 Abbott laboratories
19.1.1 Overviews
19.1.2 Recent Development
19.1.3 Product Portfolio & Product Launch in Last 1 Year
19.1.4 Revenue
19.2 Hologic Corporation
19.2.1 Overviews
19.2.2 Recent Development
19.2.3 Product Portfolio & Product Launch in Last 1 Year
19.2.4 Revenue
19.3 Becton
19.3.1 Overviews
19.3.2 Recent Development
19.3.3 Product Portfolio & Product Launch in Last 1 Year
19.3.4 Revenue
19.4 Siemens AG
19.4.1 Overviews
19.4.2 Recent Development
19.4.3 Product Portfolio & Product Launch in Last 1 Year
19.4.4 Revenue
19.5 Roche Diagnostics
19.5.1 Overviews
19.5.2 Recent Development
19.5.3 Product Portfolio & Product Launch in Last 1 Year
19.5.4 Revenue
19.6 Quest Diagnostics
19.6.1 Overviews
19.6.2 Recent Development
19.6.3 Product Portfolio & Product Launch in Last 1 Year
19.6.4 Revenue
19.7 Cardinal Health
19.7.1 Overviews
19.7.2 Recent Development
19.7.3 Product Portfolio & Product Launch in Last 1 Year
19.7.4 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com